Companies › Ikaria Bioscience
3 active drug programs in 3 registered trials: 3 Phase 1; Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RN3161 | – | Phase 1 | Obesity &Amp; Overweight | Feb 2027 |
| RN5681 | – | Phase 1 | High Cholesterol | Feb 2027 |
| RN0361 | – | Phase 1 | Hypertriglyceridemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06471543 | RN0361 | Phase 1 | Hypertriglyceridemia | Metabolic and endocrine | Jun 2026 |
| NCT07245771 | RN3161 | Phase 1 | Obesity &Amp; Overweight | Metabolic and endocrine | Feb 2027 |
| NCT07347678 | RN5681 | Phase 1 | High Cholesterol | Metabolic and endocrine | Feb 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.